

## Perspective



# Unique properties of tissue-resident memory T cells in the lungs: implications for COVID-19 and other respiratory diseases

Francis R. Carbone

## Abstract

Tissue-resident memory T ( $T_{RM}$ ) cells were originally identified as a tissue-sequestered population of memory T cells that show lifelong persistence in non-lymphoid organs. That definition has slowly evolved with the documentation of  $T_{RM}$  cells having variable terms of tissue residency combined with a capacity to return to the wider circulation. Nonetheless, reductionist experiments have identified an archetypical population of  $T_{RM}$  cells showing intrinsic permanent residency in a wide range of non-lymphoid organs, with one notable exception: the lungs. Despite the fact that memory T cells generated during a respiratory infection are maintained in the circulation, local  $T_{RM}$  cell numbers in the lung decline concomitantly with a decay in T cell-mediated protection. This Perspective describes the mechanisms that underpin long-term T cell lodgement in non-lymphoid tissues and explains why residency is transient for select  $T_{RM}$  cell subsets. In doing so, it highlights the unusual nature of memory T cell egress from the lungs and speculates on the broader disease implications of this process, especially during infection with SARS-CoV-2.

## Sections

### Introduction

### Identifying tissue-resident memory T cells

### $CD103^+CD8^+$ $T_{RM}$ cells: the archetypical $T_{RM}$ cell

### $RUNX3$ and $TGF\beta$ in $CD8^+$ $T_{RM}$ cell development

### $T_{RM}$ cell re-entry into the circulation

### $T_{RM}$ cells in the lungs

### $T_{RM}$ cell lung egress and immunity to SARS-CoV-2

### Conclusion

## Introduction

Memory T cells can show a range of persistence within non-lymphoid compartments. Many lymphocytes move freely through the various organs unimpeded before exiting the tissue via the draining lymphatic vessels<sup>1–3</sup>. Recognition of antigen leads to their transient retention<sup>4</sup> while physical barriers may slow the return of cells to the circulation<sup>5</sup>. Finally, a subset of T cells is specialized for purely localized patterns of immune surveillance<sup>6,7</sup> and only poorly exits the tissues, if at all<sup>8</sup>. These tissue-resident memory T (T<sub>RM</sub>) cells<sup>9</sup> have a cell-autonomous limitation in their recirculation capacity<sup>10–12</sup> and show a superior ability to control localized infections in a number of settings<sup>13–15</sup>. In this Perspective, I detail the transcription networks that define sequestered T<sub>RM</sub> cells, identifying CD103<sup>+</sup>CD8<sup>+</sup> memory T cells as the key population of memory CD8<sup>+</sup> T cells that encompasses all the hallmarks of permanent tissue residency. Finally, I describe how these archetypical T<sub>RM</sub> cells show an unusual pattern of egress from the lungs and discuss how this impacts the course of respiratory infections, including SARS-CoV-2.

## Identifying tissue-resident memory T cells

T<sub>RM</sub> cells were initially identified as a distinct, sessile T cell subset that coexisted alongside tissue-emigrating T cells<sup>8</sup>. This was a break from the prevailing understanding of tissue T cells based on early lymphocyte circulation experiments<sup>5,16,17</sup>. At that time, the widely accepted view was that these T cells were simply recirculating memory cells that either happened to be found in non-lymphoid tissues in large numbers<sup>18–20</sup> or, alternatively, were trapped by some sort of gating mechanisms or by structural barriers such as the basement membrane that lines epithelia<sup>5</sup>. The identification of a unique T<sub>RM</sub> cell subset meant that non-lymphoid tissues contained at least two populations of memory T cells, each with its own distinct phenotype and functional properties. One was a recirculating subset that at the time was thought to comprise effector memory T (T<sub>EM</sub>) cells<sup>17</sup> and the other, the newly identified permanently resident T<sub>RM</sub> cell population.

A major challenge from that point onwards has been distinguishing non-migrating T<sub>RM</sub> cells from recirculating memory T cells, largely because of the phenotypic overlap between these populations. For example, T<sub>RM</sub> cells do not express CC-chemokine receptor 7 (CCR7) – a receptor required for entry into lymphoid tissues and the marker that was originally used to differentiate T<sub>EM</sub> cells (identified as CCR7-negative) from lymphoid-tissue-constrained central memory T (T<sub>CM</sub>) cells (identified as CCR7-positive)<sup>17</sup>. Separately, CD69 had been proposed to be a pan-T<sub>RM</sub> cell identifier<sup>21</sup>, yet it is upregulated by both antigen-specific and nonspecific stimuli<sup>22</sup> and a substantial fraction of migratory T cells express this molecule once in the tissues<sup>23</sup>. Compounding the confusion is the extensive heterogeneity seen in both circulating and tissue-resident memory T cell populations<sup>24–27</sup>, expanded by a history of natural infection<sup>28</sup>. Therefore, although combinations of surface markers can cover a range of T<sub>RM</sub>-like tissue cells, it would be fair to say that to date there remains no unifying phenotypic identifier for this population.

## CD103<sup>+</sup>CD8<sup>+</sup> T<sub>RM</sub> cells: the archetypical T<sub>RM</sub> cell

Although it has proven difficult to identify T<sub>RM</sub> cells by definitive phenotypic means, therapeutic and experimental interventions can eliminate all circulating T cells from the blood, leaving long-term tissue residents as the only memory T cells remaining in non-lymphoid compartments. Two approaches have proven particularly useful in this regard. The first exploits T cell responses against a transplantation mismatch to selectively eliminate cells in the circulation<sup>29–31</sup> whereas the second uses

a more versatile cytolytic antibody-based technique for the same purpose<sup>27,32,33</sup>. Of additional importance is the in vivo infusion of labelling antibodies before tissue analyses to exclude cells that are simply in the vasculature<sup>34</sup>. This technique eliminates confounding contributions by blood-borne cells and is critical when examining highly vascularized organs such as the lung, although it does not identify T<sub>RM</sub> cells per se.

One of the striking features of the mouse T<sub>RM</sub> cells that remain after circulating T cells are depleted from the tissues is the dominance of a population of CD8<sup>+</sup> T cells expressing the CD103 (also known as  $\alpha$ E integrin) subunit of the  $\alpha$ E $\beta$ 7 integrin complex<sup>23,33</sup>. CD103<sup>+</sup> T<sub>RM</sub> cells are highly enriched in the environmentally exposed epithelia of the skin, small intestine and female reproductive tract<sup>8,10,35</sup>. At these epithelial sites, interaction between  $\alpha$ E $\beta$ 7 and its abundantly expressed target ligand E-cadherin<sup>36</sup> probably plays a role in cell adhesion and retention. However, CD103<sup>+</sup>CD8<sup>+</sup> T<sub>RM</sub> cells are also found in non-epithelial tissues such as the brain<sup>12,37</sup>, and although CD103 has variously been implicated as being important for T<sub>RM</sub> cell development<sup>38–40</sup>, its expression is not ubiquitous<sup>37</sup> and therefore not mandatory for all forms of T cell residency. Nonetheless, tissue-lodged CD103<sup>+</sup>CD8<sup>+</sup> memory T cells are highly resistant to equilibration across parabiotic pairs<sup>41</sup>, are uniquely spared from elimination by the approaches mentioned above<sup>23,30</sup>, selectively survive for prolonged periods in transplanted tissues in mice<sup>8,33</sup> as well as in humans<sup>42,43</sup> and persist independently of antigen recognition<sup>15,37</sup>. Moreover, CD103<sup>+</sup>CD8<sup>+</sup> memory T cells are usually not found in secondary lymphoid organs<sup>15,44</sup> – with one striking exception<sup>45,46</sup> to be described in detail below. Thus, although not all T<sub>RM</sub> cells express CD103, the balance of evidence argues that CD103<sup>+</sup>CD8<sup>+</sup> tissue T cells are true T<sub>RM</sub> cells, making this an easily identifiable archetypical population and an ideal reductionist means for delineating tissue residency mechanisms.

## RUNX3 and TGF $\beta$ in CD8<sup>+</sup> T<sub>RM</sub> cell development

Early experiments in mice comparing the transcriptomes of CD103<sup>+</sup>CD8<sup>+</sup> T<sub>RM</sub> cells isolated from a range of organs with those of their circulating counterparts provided some of the first insights into the transcription networks critical for T<sub>RM</sub> cell development and survival<sup>10,39</sup>. Not surprisingly, genes associated with tissue egress were found to be downregulated in T<sub>RM</sub> cells, including *Ccr7* and the genes encoding the sphingosine-1-phosphate receptors S1PR1 and S1PR5<sup>10,11</sup>. Without the downregulation of these receptors, the precursors of T<sub>RM</sub> cells return to the circulation, thereby dampening T<sub>RM</sub> cell development<sup>11,47</sup>. Other genes that come into play are those involved in dealing with local metabolite availability<sup>7,48,49</sup> and those that prolong T cell survival<sup>23</sup>, with both sets of genes necessary to maintain a long-lived sequestered T cell population. Further experiments fleshed out how transcription factors control the various networks, such as the involvement of KLF2, which modulates the expression of S1PR1 and CCR7<sup>11</sup>. Following this, key upstream gene regulators were identified, such as T-bet and EOMES<sup>23,50</sup> as well as BLIMP1 and the BLIMP1 homologue HOBIT<sup>51,52</sup>; of note, BLIMP1 and HOBIT are also involved in the development of innate-like lymphocytes that permanently reside in mouse tissues, such as natural killer cells and natural killer T cells<sup>51</sup>. Most recently, an overarching transcription factor has come into focus. RUNX3 has been identified as contributing to T<sub>RM</sub> cell formation, and it directly or indirectly regulates BLIMP1 and KLF2 expression as well as modulating downstream retention components<sup>53</sup>. This contribution is particularly striking as RUNX3 is a pivotal player in CD8<sup>+</sup> T cell development and functionality<sup>54,55</sup>.

As the network analyses evolved, one commonality to emerge was the involvement of TGF $\beta$  in T<sub>RM</sub> cell development and survival


in a range of tissues and organs<sup>23,40,56–58</sup>. TGF $\beta$  appears to use a non-canonical signalling pathway<sup>59</sup> that controls much of the CD8 $^+$  T<sub>RM</sub> cell gene expression signature<sup>60</sup>. It has been shown to facilitate tissue entry via selectin upregulation<sup>61</sup> and can regulate a broad range of transcription regulators and cytokine-driven survival factors during CD8 $^+$  T<sub>RM</sub> cell development<sup>11,23,50</sup>. Combined, there is now a wealth of data regarding the tenets of transcriptional control of T<sub>RM</sub> cell formation, which largely pivots around a TGF $\beta$ –RUNX3 axis, at least in the case of the mouse CD8 $^+$  T<sub>RM</sub> cell subset.

## T<sub>RM</sub> cell re-entry into the circulation

Although T<sub>RM</sub> cells were originally shown to persist in non-lymphoid organs in quasi-perpetuity<sup>8</sup>, there have been subsequent descriptions of T<sub>RM</sub> cell egress with the resultant ‘ex-T<sub>RM</sub> cells’ ultimately being incorporated into the circulation<sup>33,41,62</sup>. CD8 $^+$  T<sub>RM</sub> cell numbers show an intrinsic decline in organs such as the lung and liver<sup>30,41</sup>, but not in tissues such as the skin and small intestine, where the cells effectively remain in place for life once lodged<sup>8,41</sup>. However even for these fixed populations, T<sub>RM</sub> cells can be forced to leave using *in situ* antigen stimulation via peptide challenge<sup>33,44</sup>. Such active dislodgement is not universal, with CD103 $^+$ CD8 $^+$  T<sub>RM</sub> cells sometimes remaining resident in the tissue even after multiple rounds of cell division initiated by local infection<sup>8,63,64</sup>. Perhaps tellingly, when CD103 $^+$ CD8 $^+$  T<sub>RM</sub> cells are selectively dislodged by intervention, the resultant ex-T<sub>RM</sub> cells appear to adopt a phenotype intermediate between those of upstream resident memory T cells and conventional recirculating memory T cell populations, with a CD103 expression status that is either undefined or reported to be transient<sup>33,44</sup>. Moreover, when these same cells are directly isolated from non-lymphoid compartments, they are inferior in their capacity to enter the circulation compared to counterparts extracted from lymphoid organs<sup>33,65</sup>.

It remains difficult to reconcile these conflicting results, but studies on CD8 $^+$  T<sub>RM</sub> cells in the liver and recent revelations regarding the basis for CD4 $^+$  T cell residency provide valuable insight that might explain egress variability. Although much more is known about CD8 $^+$  T<sub>RM</sub> cells, there are many examples of CD4 $^+$  T<sub>RM</sub> cell-type counterparts<sup>13,27,66</sup>. Comparisons make it clear that the two are unrelated in terms of mechanistic underpinnings and they can exhibit quite distinct patterns of tissue residency even in the same organ<sup>29,67</sup>. As noted above, the archetypical CD103 $^+$ CD8 $^+$  T<sub>RM</sub> cells use a set of TGF $\beta$ -driven transcriptional networks to shut down tissue egress, upregulate survival factors and tailor metabolic pathways. By contrast, few of these networks have been associated with CD4 $^+$  T<sub>RM</sub> cell residency, which instead relies on retention mechanisms variously operating via cell aggregation, antigen-specific T cell activation and chemotactic agents<sup>68,69</sup> (Fig. 1). The reason why CD4 $^+$  and CD8 $^+$  T<sub>RM</sub> cells are likely to differ at the mechanistic level is the pivotal role RUNX3 plays in T<sub>RM</sub> cell development and survival<sup>53</sup>. This transcription factor is repressed in CD4 $^+$  T cells by the opposing gene regulator ThPOK (also known as ZBTB7B), which is itself a lineage-determining factor<sup>70,71</sup>. Although natural RUNX3 upregulation can convert CD4 $^+$  T cells to an unconventional CD8 $\alpha\alpha^+$  intraepithelial regulatory T cell population with CD8 $^+$  T<sub>RM</sub> cell-like qualities<sup>72</sup>, the intrinsic paucity of RUNX3 expression in conventional CD4 $^+$  T<sub>RM</sub> cells results in low CD103 levels in these cells and more transient tissue residency as a direct consequence of their inability to access the RUNX3-mediated pathways downstream of TGF $\beta$  signalling<sup>53,73</sup>.

Somewhat analogous to their CD4 $^+$  tissue-resident T cell counterparts, mouse liver CD8 $^+$  T<sub>RM</sub> cells are also deficient in CD103




**Fig. 1 | Subtypes of tissue-resident memory T cells based on transcription profiles.** The mechanism promoting permanent residency in non-lymphoid tissues for the CD103 $^+$ CD8 $^+$  tissue-resident memory T (T<sub>RM</sub>) cell population involves a RUNX3-driven transcriptional network that is downstream of TGF $\beta$  receptor signalling<sup>53,60</sup>. This transcription programme is missing in CD4 $^+$  T<sub>RM</sub> cells as a consequence of deficiencies in RUNX3 expression<sup>73</sup>. Instead, these populations use a combination of cell aggregation and extrinsic chemokine networks for tissue retention<sup>68,69</sup>. The typical CD103 $^+$ CD8 $^+$  T<sub>RM</sub> cell transcription programme is also missing in CD103 $^+$  liver-like T<sub>RM</sub> cells because of deficiencies in TGF $\beta$  engagement<sup>65</sup>.

expression<sup>74</sup>. These cells show medium-to-long-term tissue residency<sup>74</sup>, but not the almost lifelong persistence of T<sub>RM</sub> cells in organs such as skin and small intestine<sup>41,65</sup>. Although the liver T cells are fully capable of responding to TGF $\beta$ , local requirements negate this capacity, resulting in an immature or less differentiated CD103 $^-$  T<sub>RM</sub> cell population (Fig. 1) with an inferior term of residency combined with more flexible reprogramming compared to mature CD103 $^+$  T<sub>RM</sub> cell counterparts<sup>65</sup>. Collectively, the results show that although CD103 $^-$  T<sub>RM</sub> cells can reside in tissues for a considerable period, they can exhibit a range of spontaneous egress and reprogramming capabilities because of deficiencies in TGF $\beta$ -mediated maturation. Given the heterogeneous nature of tissue-resident T cells, including variable CD103 $^+$  T cell content across different organs<sup>37</sup> and the known recruitment of recirculating T cells by the peptide stimulation used for T<sub>RM</sub> cell dislodgement<sup>32</sup>, it is possible that less differentiated populations analogous to the liver CD103 $^-$  T<sub>RM</sub> cells may preferentially contribute to the egress process. Regardless, although some T<sub>RM</sub> cells can leave the tissues and enter the circulation, the balance of data argues that for the archetypical CD103 $^+$ CD8 $^+$  T<sub>RM</sub> cells, this process is not constitutive and when it does happen, it usually results in cells that do not phenocopy their direct upstream antecedents.

## T<sub>RM</sub> cells in the lungs

From the discussion above, it can be reasonably argued that because they fully engage the TGF $\beta$ –RUNX3 residency programme, mouse CD103 $^+$ CD8 $^+$  tissue T cells fit the original T<sub>RM</sub> cell definition<sup>8</sup>; specifically,



**Fig. 2 | Selective and constitutive egress of lung CD103<sup>+</sup>CD8<sup>+</sup>T<sub>RM</sub> cells.**

Inflammation associated with infection of tissues such as skin, small intestine and reproductive tract (left panels) and lung (right panels) leads to the recruitment of a variety of CD4<sup>+</sup> and CD8<sup>+</sup> T cells that combat the invading pathogens (part a). These populations include effector memory T (T<sub>EM</sub>) cells that continuously recirculate between non-lymphoid organs and blood as well as tissue-resident memory T (T<sub>RM</sub>) cell precursors (not shown). Following resolution of the infection (part b), most of the recruited T cells exit or die, leaving local immunosurveillance

to recirculating T<sub>EM</sub> cells and the more potent T<sub>RM</sub> cells. Over time, some T<sub>RM</sub> cell subsets selectively disappear (part c, left panel), resulting in a resident population highly enriched in long-lived CD103<sup>+</sup>CD8<sup>+</sup>T<sub>RM</sub> cells that afford long-term local immunity against re-infection (part d, left panel). In the lungs, CD103<sup>+</sup>CD8<sup>+</sup>T<sub>RM</sub> cells are gradually lost after the infection has resolved and instead accumulate in the proximal draining lymph nodes (part c, right panel) leaving the lower respiratory tract deficient in CD103<sup>+</sup>CD8<sup>+</sup>T<sub>RM</sub> cells and thus susceptible to re-infection (part d, right panel).

they form a distinct subset of memory T cells that remains lodged in peripheral compartments in virtual perpetuity. However, there is one organ where the CD103<sup>+</sup>CD8<sup>+</sup> T cells do not abide by this rule, and its uniqueness has important disease implications. Unlike the situation in other tissues, CD103<sup>+</sup>CD8<sup>+</sup>T<sub>RM</sub> cells in the lung do not require local antigen stimulation for dislodgement<sup>45</sup>. Also unusually, the egressing

memory T cells retain cell surface expression of CD103 post-exit, meaning that the lung-draining lymph nodes are unique in having a substantive subset of memory CD8<sup>+</sup> T cells with this marker<sup>45,46</sup>. Lung CD103<sup>+</sup>CD8<sup>+</sup>T<sub>RM</sub> cells are fully mature and unremarkable in terms of their TGF $\beta$  requirement for development and survival<sup>38</sup>. They also express the gene signatures associated with tissue residency<sup>10,12</sup>,

including a cluster of  $T_{RM}$  cell-associated transcription factors, namely HOBIT, NR4A1, aryl hydrocarbon receptor (AhR) and BHLHE40<sup>75,76</sup>. In all critical aspects, they resemble  $T_{RM}$  cells from other tissues, meaning that their exit from the lung is probably an organ-specific feature rather than due to a cell-intrinsic programme. Such a mechanistic distinction is important, as it would suggest that the egress process would probably capture  $T_{RM}$  cells beyond the archetypical CD103<sup>+</sup>CD8<sup>+</sup> subset that was used to define this phenomenon and would do so regardless of where they fall on a maturation and term-of-residency continuum.

Exacting experiments by Stolley and colleagues<sup>45</sup> proved that the resultant draining lymph node-resident memory T cells were indeed constitutively derived from upstream lung tissue counterparts, possibly dislodged as a consequence of virus-induced tissue damage<sup>77,78</sup> or the interruption of tonic TGF $\beta$  signalling needed to retain  $T_{RM}$  cells in tissues<sup>79</sup>. Although the resultant lymph node accumulation offers an additional avenue to maintain regional protection<sup>45,80</sup>, memory T cell exit helps to explain one of the intriguing conundrums associated with immune protection in the lungs. It has long been known that T cell immunity in the lung wanes over time, with this first reported for respiratory infections with influenza virus and Sendai virus in mice<sup>81,82</sup>. This decline in lung-based immunity occurs despite virus-specific memory cells persisting in the circulation<sup>30,82–84</sup>. Non- $T_{RM}$  cell-based mechanisms were originally proposed to describe the behaviour of lung T cell populations<sup>81,85–87</sup>, variously confounded by blood-borne cells that are particularly problematic when dealing with this highly vascularized organ<sup>34</sup>. More recently, it was shown that the waning local immunity correlates with declining lung  $T_{RM}$  cell numbers in mouse after influenza virus infection<sup>83,84</sup> and in humans after respiratory syncytial virus challenge<sup>88</sup>. Although other mechanisms have been posited to account for this  $T_{RM}$  cell attrition, such as the selective death of lung  $T_{RM}$  cells<sup>30,84</sup> or the disappearance of structures associated with focal damage<sup>67</sup>, none exclude concurrent tissue egress. Once lost, lung  $T_{RM}$  cells are difficult to replace in the absence of renewed infection owing to the strict antigen recognition requirements for effective lodgement<sup>67,83,89</sup>, which are optional in many other tissues<sup>37</sup> including the upper respiratory tract<sup>90</sup>. Overall, a range of mechanistic overlays would imply that losing  $T_{RM}$  cells over time is important for this organ – for example, to limit ongoing damage to its delicate oxygen-exchange architecture<sup>91</sup>.

Finally, the natural decay of lung  $T_{RM}$  cells stands in stark contrast to what is seen elsewhere in the body, where CD103<sup>+</sup>CD8<sup>+</sup>  $T_{RM}$  cell populations can remain tightly contained (Fig. 2). CD103<sup>+</sup>CD8<sup>+</sup>  $T_{RM}$  cells show long-term persistence in organs such as the brain, skin and cervicovaginal tissue<sup>8,39,92</sup>, despite the loss of their CD103<sup>-</sup> counterparts. The extent to which these spatial and temporal restrictions can operate was dramatically illustrated by experiments that lodged CD103<sup>+</sup>CD8<sup>+</sup>  $T_{RM}$  cells in a small patch of skin, thus confining effective protection to just that location while leaving the remainder of the torso under the inferior control of memory cells in the blood<sup>8,63</sup>. By contrast, lung  $T_{RM}$  cell residency is unstable and transient, resulting in surveillance that is increasingly dependent on recirculating populations over time, with a concomitant decline in local T cell immunity.

## $T_{RM}$ cell lung egress and immunity to SARS-CoV-2

At the time of this writing and nearly three years since the emergence of the SARS-CoV-2 virus in late 2019<sup>93,94</sup>, the COVID-19 pandemic continues to be a major challenge in many parts of the world. Despite reports showing that circulating antiviral T cell immunity can be cross-reactive against emerging variants<sup>95</sup>, long lived<sup>96,97</sup> and associated with better

disease outcomes<sup>98,99</sup>, immunity from combinations of COVID-19 vaccination and SARS-CoV-2 infection has been found to steadily decline<sup>100,101</sup>. One possible contributor may be that anti-SARS-CoV-2 tissue-resident T cells that are pivotal for immune protection show the same type of numerical decay as reported for mouse CD103<sup>+</sup>CD8<sup>+</sup>  $T_{RM}$  cells. Employing strategies that slow  $T_{RM}$  cell loss<sup>102</sup> could be advantageous, as might approaches that circumvent the lung altogether. The upper respiratory tract, especially the nasal mucosa, is a prime target with respect to the latter possibility as it does not show the  $T_{RM}$  cell decline that is intrinsic to the lung<sup>90</sup>. Alternatively, it may be that  $T_{RM}$  cells are actually counterproductive, leading to tissue damage. This is especially poignant because repeated antigen encounters extend the durability of CD103<sup>+</sup>CD8<sup>+</sup>  $T_{RM}$  cells in the lung<sup>102</sup>, yet a recent report found that experiencing successive SARS-CoV-2 infections progressively increases the risk of adverse health outcomes<sup>103</sup>. In terms of their potential to contribute to tissue damage, TRM cells have an innate immune alarm and recruitment function<sup>32,104</sup>, and the innate response has been shown to be a key mediator of COVID-19-associated lung pathology<sup>105,106</sup>.

## Conclusion

Overall,  $T_{RM}$  cells provide superior protection against tissue-localized infection, primarily because of constraints in their migration capabilities. Despite proving to be long-lived and effective in a range of different infectious diseases, lung  $T_{RM}$  cells have an unusual propensity for tissue exit reflected in a decay in local T cell immunity. Such a feature may have evolved to protect this organ against long-term damage or may simply be a by-product of some unique anatomical feature intrinsic to lung function. Given the ability of  $T_{RM}$  cells to respond to infection with an immediacy unmatched by the blood-based memory populations, there is a need to focus on their deposition in the different compartments of the respiratory system, especially in settings or sub-regions that support their long-term survival.

Published online: 9 December 2022

## References

1. Gowans, J. L. & Knight, E. J. The route of re-circulation of lymphocytes in the rat. *Proc. R. Soc. Lond. B Biol. Sci.* **159**, 257–282 (1964).
2. Issekutz, T. B., Chin, W. & Hay, J. B. The characterization of lymphocytes migrating through chronically inflamed tissues. *Immunology* **46**, 59–66 (1982).
3. Rannie, G. H. & Ford, W. L. Recirculation of lymphocytes: its role in implementing immune responses in the skin. *Lymphology* **11**, 193–201 (1978).
4. Hall, J., Scollay, R. & Smith, M. Studies on the lymphocytes of sheep. I. Recirculation of lymphocytes through peripheral lymph nodes and tissues. *Eur. J. Immunol.* **6**, 117–120 (1976).
5. Klonowski, K. D. et al. Dynamics of blood-borne CD8 memory T cell migration in vivo. *Immunity* **20**, 551–562 (2004).
6. Ariotti, S. et al. Tissue-resident memory CD8<sup>+</sup> T cells continuously patrol skin epithelia to quickly recognize local antigen. *Proc. Natl Acad. Sci. USA* **109**, 19739–19744 (2012).
7. Zaid, A. et al. Persistence of skin-resident memory T cells within an epidermal niche. *Proc. Natl Acad. Sci. USA* **111**, 5307–5312 (2014).
8. Gebhardt, T. et al. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. *Nat. Immunol.* **10**, 524–530 (2009).
9. Iwasaki, A. Local advantage: skin DCs prime; skin memory T cells protect. *Nat. Immunol.* **10**, 451–453 (2009).
10. Mackay, L. K. et al. The developmental pathway for CD103<sup>+</sup>CD8<sup>+</sup> tissue-resident memory T cells of skin. *Nat. Immunol.* **14**, 1294–1301 (2013).
11. Skon, C. N. et al. Transcriptional downregulation of *S1pr1* is required for the establishment of resident memory CD8<sup>+</sup> T cells. *Nat. Immunol.* **14**, 1285–1293 (2013).
12. Wakim, L. M. et al. The molecular signature of tissue resident memory CD8 T cells isolated from the brain. *J. Immunol.* **189**, 3462–3471 (2012).
13. Glennie, N. D. et al. Skin-resident memory CD4<sup>+</sup> T cells enhance protection against *Leishmania major* infection. *J. Exp. Med.* **212**, 1405–1414 (2015).
14. Jiang, X. et al. Skin infection generates non-migratory memory CD8<sup>+</sup>  $T_{RM}$  cells providing global skin immunity. *Nature* **483**, 227–231 (2012).

15. Mackay, L. K. et al. Long-lived epithelial immunity by tissue-resident memory T ( $T_{RM}$ ) cells in the absence of persisting local antigen presentation. *Proc. Natl. Acad. Sci. USA* **109**, 7037–7042 (2012).
16. Mackay, C. R., Marston, W. L. & Dudler, L. Naive and memory T cells show distinct pathways of lymphocyte recirculation. *J. Exp. Med.* **171**, 801–817 (1990).
17. Sallusto, F., Lenig, D., Forster, R., Lipp, M. & Lanzavecchia, A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. *Nature* **401**, 708–712 (1999).
18. Clark, R. A. et al. The vast majority of CLA<sup>+</sup> T cells are resident in normal skin. *J. Immunol.* **176**, 4431–4439 (2006).
19. Masopust, D., Veys, V., Marzo, A. L. & Lefrancois, L. Preferential localization of effector memory cells in nonlymphoid tissue. *Science* **291**, 2413–2417 (2001).
20. Reinhardt, R. L., Khoruts, A., Merica, R., Zell, T. & Jenkins, M. K. Visualizing the generation of memory CD4 T cells in the whole body. *Nature* **410**, 101–105 (2001).
21. Sathaliyawala, T. et al. Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets. *Immunity* **38**, 187–197 (2013).
22. Shiow, L. R. et al. CD69 acts downstream of interferon- $\alpha/\beta$  to inhibit S1P1 and lymphocyte egress from lymphoid organs. *Nature* **440**, 540–544 (2006).
23. Mackay, L. K. et al. T-box transcription factors combine with the cytokines TGF- $\beta$  and IL-15 to control tissue-resident memory T cell fate. *Immunity* **43**, 1101–1111 (2015).
24. Gerlach, C. et al. The chemokine receptor CX3CR1 defines three antigen-experienced CD8 T cell subsets with distinct roles in immune surveillance and homeostasis. *Immunity* **45**, 1270–1284 (2016).
25. Hikono, H. et al. Activation phenotype, rather than central- or effector-memory phenotype, predicts the recall efficacy of memory CD8<sup>+</sup> T cells. *J. Exp. Med.* **204**, 1625–1636 (2007).
26. Olson, J. A., McDonald-Hyman, C., Jameson, S. C. & Hamilton, S. E. Effector-like CD8<sup>+</sup> T cells in the memory population mediate potent protective immunity. *Immunity* **38**, 1250–1260 (2013).
27. Watanabe, R. et al. Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells. *Sci. Transl. Med.* **7**, 279ra39 (2015).
28. Beura, L. K. et al. Normalizing the environment recapitulates adult human immune traits in laboratory mice. *Nature* **532**, 512–516 (2016).
29. Gebhardt, T. et al. Different patterns of peripheral migration by memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells. *Nature* **477**, 216–219 (2011).
30. Slutter, B. et al. Dynamics of influenza-induced lung-resident memory T cells underlie waning heterosubtypic immunity. *Sci. Immunol.* <https://doi.org/10.1126/sciimmunol.aag2031> (2017).
31. Takamura, S. et al. Interstitial-resident memory CD8<sup>+</sup> T cells sustain frontline epithelial memory in the lung. *J. Exp. Med.* **216**, 2736–2747 (2019).
32. Schenkel, J. M., Fraser, K. A., Veys, V. & Masopust, D. Sensing and alarm function of resident memory CD8<sup>+</sup> T cells. *Nat. Immunol.* **14**, 509–513 (2013).
33. Fonseca, R. et al. Developmental plasticity allows outside-in immune responses by resident memory T cells. *Nat. Immunol.* **21**, 412–421 (2020).
34. Anderson, K. G. et al. Cutting edge: intravascular staining redefines lung CD8 T cell responses. *J. Immunol.* **189**, 2702–2706 (2012).
35. Masopust, D. et al. Dynamic T cell migration program provides resident memory within intestinal epithelium. *J. Exp. Med.* **207**, 553–564 (2010).
36. Cepek, K. L. et al. Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the  $\alpha$ E $\beta$ 7 integrin. *Nature* **372**, 190–193 (1994).
37. Casey, K. A. et al. Antigen-independent differentiation and maintenance of effector-like resident memory T cells in tissues. *J. Immunol.* **188**, 4866–4875 (2012).
38. Schon, M. P. et al. Mucosal T lymphocyte numbers are selectively reduced in integrin  $\alpha$ E $\beta$ 7-deficient mice. *J. Immunol.* **162**, 6641–6649 (1999).
39. Wakim, L. M., Woodward-Davis, A. & Bevan, M. J. Memory T cells persisting within the brain after local infection show functional adaptations to their tissue of residence. *Proc. Natl. Acad. Sci. USA* **107**, 17872–17879 (2010).
40. Lee, Y. T. et al. Environmental and antigen receptor-derived signals support sustained surveillance of the lungs by pathogen-specific cytotoxic T lymphocytes. *J. Virol.* **85**, 4085–4094 (2011).
41. Wijeyesinghe, S. et al. Expansible residence decentralizes immune homeostasis. *Nature* **592**, 457–462 (2021).
42. Lian, C. G. et al. Biomarker evaluation of face transplant rejection: association of donor T cells with target cell injury. *Mod. Pathol.* **27**, 788–799 (2014).
43. Snyder, M. E. et al. Generation and persistence of human tissue-resident memory T cells in lung transplantation. *Sci. Immunol.* <https://doi.org/10.1126/sciimmunol.aav5581> (2019).
44. Beura, L. K. et al. T cells in nonlymphoid tissues give rise to lymph-node-resident memory T cells. *Immunity* **48**, 327–338e5 (2018).
45. Stolley, J. M. et al. Retrograde migration supplies resident memory T cells to lung-draining LN after influenza infection. *J. Exp. Med.* <https://doi.org/10.1084/jem.20192197> (2020).
46. Takamura, S. et al. The route of priming influences the ability of respiratory virus-specific memory CD8<sup>+</sup> T cells to be activated by residual antigen. *J. Exp. Med.* **207**, 1153–1160 (2010).
47. Evrard, M. et al. Sphingosine 1-phosphate receptor 5 (S1PR5) regulates the peripheral retention of tissue-resident lymphocytes. *J. Exp. Med.* <https://doi.org/10.1084/jem.20210116> (2022).
48. Pan, Y. et al. Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism. *Nature* **543**, 252–256 (2017).
49. Frizzell, H. et al. Organ-specific isoform selection of fatty acid-binding proteins in tissue-resident lymphocytes. *Sci. Immunol.* <https://doi.org/10.1126/sciimmunol.aay9283> (2020).
50. Laidlaw, B. J. et al. CD4<sup>+</sup> T cell help guides formation of CD103<sup>+</sup> lung-resident memory CD8<sup>+</sup> T cells during influenza viral infection. *Immunity* **41**, 633–645 (2014).
51. Mackay, L. K. et al. Hobit and Blimp1 instruct a universal transcriptional program of tissue residency in lymphocytes. *Science* **352**, 459–463 (2016).
52. Parga-Vidal, L. et al. Hobit identifies tissue-resident memory T cell precursors that are regulated by Eomes. *Sci. Immunol.* <https://doi.org/10.1126/sciimmunol.abg3533> (2021).
53. Milner, J. J. et al. Runx3 programs CD8<sup>+</sup> T cell residency in non-lymphoid tissues and tumours. *Nature* **552**, 253–257 (2017).
54. Cruz-Guilloty, F. et al. Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. *J. Exp. Med.* **206**, 51–59 (2009).
55. Taniuchi, I. et al. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. *Cell* **111**, 621–633 (2002).
56. Sheridan, B. S. et al. Oral infection drives a distinct population of intestinal resident memory CD8<sup>+</sup> T cells with enhanced protective function. *Immunity* **40**, 747–757 (2014).
57. Zhang, N. & Bevan, M. J. Transforming growth factor- $\beta$  signaling controls the formation and maintenance of gut-resident memory T cells by regulating migration and retention. *Immunity* **39**, 687–696 (2013).
58. Wakim, L. M., Smith, J., Caminschi, I., Lahoud, M. H. & Villadangos, J. A. Antibody-targeted vaccination to lung dendritic cells generates tissue-resident memory CD8<sup>+</sup> T cells that are highly protective against influenza virus infection. *Mucosal Immunol.* **8**, 1060–1071 (2015).
59. Hu, Y., Lee, Y. T., Kaech, S. M., Garvy, B. & Cauley, L. S. Smad4 promotes differentiation of effector and circulating memory CD8<sup>+</sup> T cells but is dispensable for tissue-resident memory CD8<sup>+</sup> T cells. *J. Immunol.* **194**, 2407–2414 (2015).
60. Nath, A. P. et al. Comparative analysis reveals a role for TGF- $\beta$  in shaping the residency-related transcriptional signature in tissue-resident memory CD8<sup>+</sup> T cells. *PLoS ONE* **14**, e0210495 (2019).
61. Ma, C., Mishra, S., Demel, E. L., Liu, Y. & Zhang, N. TGF- $\beta$  controls the formation of kidney-resident T cells via promoting effector T cell extravasation. *J. Immunol.* **198**, 749–756 (2017).
62. Klicznik, M. M. et al. Human CD4<sup>+</sup>CD103<sup>+</sup> cutaneous resident memory T cells are found in the circulation of healthy individuals. *Sci. Immunol.* <https://doi.org/10.1126/sciimmunol.aav8995> (2019).
63. Park, S. L. et al. Local proliferation maintains a stable pool of tissue-resident memory T cells after antiviral recall responses. *Nat. Immunol.* **19**, 183–191 (2018).
64. Wakim, L. M., Waithman, J., van Rooijen, N., Heath, W. R. & Carbone, F. R. Dendritic cell-induced memory T cell activation in nonlymphoid tissues. *Science* **319**, 198–202 (2008).
65. Christo, S. N. et al. Discrete tissue microenvironments instruct diversity in resident memory T cell function and plasticity. *Nat. Immunol.* **22**, 1140–1151 (2021).
66. Beura, L. K. et al. CD4<sup>+</sup> resident memory T cells dominate immunosurveillance and orchestrate local recall responses. *J. Exp. Med.* **216**, 1214–1229 (2019).
67. Takamura, S. et al. Specific niches for lung-resident memory CD8<sup>+</sup> T cells at the site of tissue regeneration enable CD69-independent maintenance. *J. Exp. Med.* **213**, 3057–3073 (2016).
68. Iijima, N. & Iwasaki, A. T cell memory. A local macrophage chemokine network sustains protective tissue-resident memory CD4<sup>+</sup> T cells. *Science* **346**, 93–98 (2014).
69. Collins, N. et al. Skin CD4<sup>+</sup> memory T cells exhibit combined cluster-mediated retention and equilibration with the circulation. *Nat. Commun.* **7**, 11514 (2016).
70. Egawa, T. & Littman, D. R. ThPOK acts late in specification of the helper T cell lineage and suppresses Runx-mediated commitment to the cytotoxic T cell lineage. *Nat. Immunol.* **9**, 1131–1139 (2008).
71. He, X. et al. The zinc finger transcription factor Th-POK regulates CD4 versus CD8 T-cell lineage commitment. *Nature* **433**, 826–833 (2005).
72. Reis, B. S., Rogoz, A., Costa-Pinto, F. A., Taniuchi, I. & Mucida, D. Mutual expression of the transcription factors Runx3 and ThPOK regulates intestinal CD4<sup>+</sup> T cell immunity. *Nat. Immunol.* **14**, 271–280 (2013).
73. Fonseca, R. et al. Runx3 drives a CD8<sup>+</sup> T cell tissue residency program that is absent in CD4<sup>+</sup> T cells. *Nat. Immunol.* **23**, 1236–1245 (2022).
74. Fernandez-Ruiz, D. et al. Liver-resident memory CD8<sup>+</sup> T cells form a front-line defense against malaria liver-stage infection. *Immunity* **45**, 889–902 (2016).
75. Bodduupalli, C. S. et al. ABC transporters and NR4A1 identify a quiescent subset of tissue-resident memory T cells. *J. Clin. Invest.* **126**, 3905–3916 (2016).
76. Li, C. et al. The transcription factor Blhhe40 programs mitochondrial regulation of resident CD8<sup>+</sup> T cell fitness and functionality. *Immunity* **51**, 491–507.e7 (2019).
77. Quantius, J. et al. Influenza virus infects epithelial stem/progenitor cells of the distal lung: impact on Fgf2b-driven epithelial repair. *PLoS Pathog.* **12**, e1005544 (2016).
78. Ray, S. et al. Rare SOX2<sup>+</sup> airway progenitor cells generate KRT5<sup>+</sup> cells that repopulate damaged alveolar parenchyma following influenza virus infection. *Stem Cell Rep.* **7**, 817–825 (2016).
79. Hirai, T. et al. Competition for active TGF $\beta$  cytokine allows for selective retention of antigen-specific tissue-resident memory T cells in the epidermal niche. *Immunity* **54**, 84–98.e5 (2021).
80. Anthony, S. M. et al. Protective function and durability of mouse lymph node-resident memory CD8<sup>+</sup> T cells. *eLife* <https://doi.org/10.7554/eLife.68662> (2021).
81. Hogan, R. J. et al. Activated antigen-specific CD8<sup>+</sup> T cells persist in the lungs following recovery from respiratory virus infections. *J. Immunol.* **166**, 1813–1822 (2001).

82. Liang, S., Mozdzanowska, K., Palladino, G. & Gerhard, W. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. *J. Immunol.* **152**, 1653–1661 (1994).
83. Wu, T. et al. Lung-resident memory CD8 T cells ( $T_m$ ) are indispensable for optimal cross-protection against pulmonary virus infection. *J. Leukoc. Biol.* **95**, 215–224 (2014).
84. Hayward, S. L. et al. Environmental cues regulate epigenetic reprogramming of airway-resident memory CD8<sup>+</sup> T cells. *Nat. Immunol.* **21**, 309–320 (2020).
85. Ely, K. H. et al. Nonspecific recruitment of memory CD8<sup>+</sup> T cells to the lung airways during respiratory virus infections. *J. Immunol.* **170**, 1423–1429 (2003).
86. Tripp, R. A., Hou, S. & Doherty, P. C. Temporal loss of the activated L-selectin-low phenotype for virus-specific CD8<sup>+</sup> memory T cells. *J. Immunol.* **154**, 5870–5875 (1995).
87. Roberts, A. D., Ely, K. H. & Woodland, D. L. Differential contributions of central and effector memory T cells to recall responses. *J. Exp. Med.* **202**, 123–133 (2005).
88. Jozwik, A. et al. RSV-specific airway resident memory CD8<sup>+</sup> T cells and differential disease severity after experimental human infection. *Nat. Commun.* **6**, 10224 (2015).
89. Wakim, L. M., Gupta, N., Mintern, J. D. & Villadangos, J. A. Enhanced survival of lung tissue-resident memory CD8<sup>+</sup> T cells during infection with influenza virus due to selective expression of IFITM3. *Nat. Immunol.* **14**, 238–245 (2013).
90. Pizzolla, A. et al. Resident memory CD8<sup>+</sup> T cells in the upper respiratory tract prevent pulmonary influenza virus infection. *Sci. Immunol.* <https://doi.org/10.1126/sciimmunol.aam6970> (2017).
91. Van Braeckel-Budimir, N. & Harty, J. T. Influenza-induced lung  $T_m$ : not all memories last forever. *Immunol. Cell Biol.* **95**, 651–655 (2017).
92. Dave, V. A. et al. Cervicovaginal tissue residence confers a distinct differentiation program upon memory CD8 T cells. *J. Immunol.* **206**, 2937–2948 (2021).
93. Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. *N. Engl. J. Med.* **382**, 727–733 (2020).
94. Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* **395**, 497–506 (2020).
95. Tarke, A. et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. *Cell* **185**, 847–859.e11 (2022).
96. Cohen, K. W. et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. *Cell Rep. Med.* **2**, 100354 (2021).
97. Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science* <https://doi.org/10.1126/science.abf4063> (2021).
98. Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. *Cell* **183**, 158–168.e14 (2020).
99. Rydzynski, M., Moderbacher, C. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. *Cell* **183**, 996–1012.e19 (2020).
100. Gazit, S. et al. SARS-CoV-2 naturally acquired immunity vs. vaccine-induced immunity, reinfections versus breakthrough infections: a retrospective cohort study. *Clin. Infect. Dis.* <https://doi.org/10.1093/cid/ciac262> (2022).
101. Goldberg, Y. et al. Protection and waning of natural and hybrid immunity to SARS-CoV-2. *N. Engl. J. Med.* **386**, 2201–2212 (2022).
102. Van Braeckel-Budimir, N., Varga, S. M., Badovinac, V. P. & Harty, J. T. Repeated antigen exposure extends the durability of influenza-specific lung-resident memory CD8<sup>+</sup> T cells and heterosubtypic immunity. *Cell Rep.* **24**, 3374–3382.e3 (2018).
103. Bowe, B., Xie, T. & Al-Aly, Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. *Nat. Med.* <https://doi.org/10.1038/s41591-022-02051-3> (2022).
104. Ariotti, S. et al. T cell memory. Skin-resident memory CD8<sup>+</sup> T cells trigger a state of tissue-wide pathogen alert. *Science* **346**, 101–105 (2014).
105. Merad, M. & Martin, J. C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. *Nat. Rev. Immunol.* **20**, 355–362 (2020).
106. Hu, B., Huang, S. & Yin, L. The cytokine storm and COVID-19. *J. Med. Virol.* **93**, 250–256 (2021).

## Acknowledgements

The author wishes to thank L. Mackay, L. Wakim and T. Gebhardt for insightful discussions.

## Competing interests

The author declares no competing interests.

## Additional information

**Correspondence** should be addressed to Francis R. Carbone.

**Peer review information** *Nature Reviews Immunology* thanks J. Harty, M. Hassett and J. Schenkel for their contribution to the peer review of this work.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

© Springer Nature Limited 2022